Non-small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which develops in the lungs and can cause symptoms like persistent cough, chest pain, and difficulty breathing.
Zoldonrasib for RAS G12D-Mutant Non-Small Cell Lung Cancer
We are studying the effects of zoldonrasib in patients with RAS G12D-mutant non-small cell lung cancer who have been previously treated. The goal is to see how well it works and how safe it is compared to existing treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have non-small cell lung cancer (NSCLC) with a RAS-G12D mutation?
- Have you had any cancer treatment before or are you unable to tolerate regular treatments?
- Do you have at least one measurable tumor (lesion)?
- Have you had any major surgery in the last 4 weeks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
RMC-9805
Cyclopentyl Aziridine
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Stadt Wien Wiener Gesundheitsverbund
c/o Klinik Floridsdorf Abteilung für Innere Medizin und Lungenforschung
Langenzersdorf, Austria
Noe LGA Gesundheit Region Mitte GmbH
Klinische Abteilung für Innere Medizin 1
Sankt Pölten, Austria
Nemocnice AGEL Novy Jicin a.s.
Nový Jičín, Czechia
Sponsor: Revolution Medicines Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.